Gene fusion characteristics and their targeted therapeutic potential in gastric cancer based on comprehensive DNA and RNA NGS analysis
10.3760/cma.j.cn431274-20250829-01114
- VernacularTitle:基于DNA与RNA NGS综合分析胃癌的基因融合特征及其靶向治疗潜力
- Author:
Jiao FENG
1
;
Houquan TAO
;
Zaiyuan YE
Author Information
1. 浙江省人民医院（杭州医学院附属人民医院）胃肠胰外科，杭州 310014
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Gene fusion;
Targeted therapy;
Next-generation sequencing
- From:
Journal of Chinese Physician
2025;27(10):1459-1463
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To reveal the molecular characteristics of gene fusions in gastric cancer and their potential targeted therapeutic value, and to develop new targeted treatment strategies for advanced gastric cancer.Methods:Tumor tissue samples from 50 fusion-positive gastric cancer patients admitted to the Zhejiang Provincial People′s Hospital from January 2018 to December 2024 were retrospectively included. Next-generation sequencing (NGS) technologies for DNA and RNA were used to analyze gene fusion events in these 50 patients.Results:A total of 53 gene fusion events were detected in the 50 gastric cancer samples, among which 73.6%(39) were druggable fusion types. The main types included FGFR (25.6%, 10/39), NTRK (15.4%, 6/39), MET (12.8%, 5/39), and ROS1 (12.8%, 5/39). Further verification by RNA NGS showed that some gene fusion events could not be confirmed at the transcript level, indicating that there was a certain false positive rate in DNA-level detection. Conclusions:This study provides new molecular targets for personalized targeted therapy of gastric cancer, especially new clinical application prospects for targeted therapy of genes such as FGFR, NTRK, MET, and ROS1. It also emphasizes the importance of RNA NGS in the detection of gene fusions in gastric cancer, which can effectively supplement and correct the false positive signals of DNA NGS and further improve the detection accuracy.
